Article
Immunology
Yasuhiro Umeyama, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Hiromi Tomono, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Mohammed S. O. Tagod, Masashi Iwasaki, Yoshimasa Tanaka, Hiroshi Mukae
Summary: Malignant pleural mesothelioma (MPM) is a rare and aggressive thoracic tumor with limited treatment options. Immune checkpoint inhibitors show promise in some patients, but the majority have only modest response rates. Developing innovative therapies, including immune effector cell-based therapies, is crucial for MPM.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Stefanie Renken, Takahiro Nakajima, Isabelle Magalhaes, Jonas Mattsson, Andreas Lundqvist, Elias S. J. Arner, Rolf Kiessling, Stina Linnea Wickstrom
Summary: Auranofin can significantly reduce intracellular ROS accumulation in human cytotoxic lymphocytes ex vivo, preserving their antitumoral activity and increasing resistance to oxidative stress.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Debora Basilio-Queiros, Eva Mischak-Weissinger
Summary: Natural Killer (NK) cells have evolved significantly since their initial discovery in the 1970s. Recent research has revealed adaptive-like behavior in NK cells, challenging the traditional categorization of the immune system. This subpopulation of NK cells exhibits characteristics of both innate and adaptive immunity, with clonal-like expansion and enhanced cytotoxic response upon antigen exposure. The implications of these findings are highly relevant in clinical settings, particularly in adoptive immunotherapies where NK cells offer distinct advantages. This review provides an overview of the discovery and current understanding of adaptive NK cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Annelisa M. Cornel, Ester Dunnebach, Damon A. Hofman, Sanjukta Das, Satyaki Sengupta, Femke van den Ham, Judith Wienke, Josephine G. M. Strijker, Denise A. M. H. van den Beemt, Anke H. W. Essing, Bianca Koopmans, Sem A. G. Engels, Vania Lo Presti, Celina S. Szanto, Rani E. George, Jan J. Molenaar, Sebastiaan van Heesch, Miranda P. Dierselhuis, S. Nierkens
Summary: This study explores the potential of combining immunotherapy with histone deacetylase inhibitors (HDACi) to enhance T cell-driven and NK cell-driven immune responses in high-risk neuroblastoma (HR-NBL). Screening drug repurposing libraries, the researchers identified compounds that upregulated major histocompatibility complex class I (MHC-I) surface expression in NBL cells. Treatment with HDACi enhanced the cytotoxic capacity of tumor-specific T cells against NBL in vitro and increased the expression of factors regulating T cell and NK cell cytotoxicity. The findings suggest a promising strategy to enhance immune responses in patients with HR-NBL through (immuno)therapy and HDACi.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Abbass Darwich, Alessandra Silvestri, Mohamed-Reda Benmebarek, Juliette Mouries, Bruno Cadilha, Alessia Melacarne, Lapo Morelli, Domenico Supino, Alexandre Taleb, Hannah Obeck, Claudio Sustmann, Agnese Losurdo, Giovanna Masci, Giuseppe Curigliano, Sebastian Kobold, Giuseppe Penna, Maria Rescigno
Summary: The study found that CHI3L1 in the serum of Trastuzumab-resistant HER2+ patients can inhibit NK cell's ADCC, leading to immune escape in cancer. CHI3L1 hinders the correct polarization of lytic granules, affecting the immune response, and targeting CHI3L1 could enhance therapeutic efficacy in antibody and cell-based immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Yi Hu, Qinglin Hu, Yongsheng Li, Ligong Lu, Zheng Xiang, Zhinan Yin, Dieter Kabelitz, Yangzhe Wu
Summary: This review comprehensively examines the immunological role of gamma delta T cells in diseases and proposes future strategies for utilizing their therapeutic potential.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Immunology
Siqi Liu, Lanlan Yang, Shengnan Jia, Rui Zhao, Zhenjing Jin
Summary: In patients with hepatocellular carcinoma (HCC), the levels of NKB cells and IL-18 secretion were decreased in both peripheral blood and liver-infiltrating sites. Elevated IL-35 levels were negatively correlated with the percentage of NKB cells and IL-18 production in HCC, suggesting a suppressive role of IL-35 on NKB cell activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Pauline Rettman, Matthew D. Blunt, Rebecca J. Fulton, Andres F. Vallejo, Leidy Y. Bastidas-Legarda, Laura Espana-Serrano, Marta E. Polak, Aymen Al-Shamkhani, Christelle Retiere, Salim Khakoo
Summary: This study demonstrates the feasibility of a peptide-based KIR-targeting vaccine strategy to activate NK cells and enhance antitumor responses. The DNA vaccine upregulated genes associated with cellular metabolism and downregulated genes related to immune cell maturation. Vaccination led to enhanced antitumor responses against melanoma cells and a tumor model expressing the KIR2DS2 ligand HLA-C*0102.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Katsiaryna Marhelava, Anna Burdzinska, Angelika Muchowicz, Agnieszka Goral, Andriy Zhylko, Karolina Soroczynska, Kuba Retecki, Marta Krawczyk, Marta Klopotowska, Zofia Pilch, Leszek Paczek, Karl-Johan Malmberg, Sebastien Walchli, Magdalena Winiarska, Radoslaw Zagozdzon
Summary: This study provides new information on the efficacy of PD-L1-targeted CAR against PD-L1(low) targets. The results show that PD-L1-CAR cells have strong reactivity and cytotoxicity against both PD-L1(high) and PD-L1(low) target cells. Additionally, PD-L1-CAR cells also exhibit potent cytotoxic effects against non-malignant cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Yu-Cheng Chang, Yi-Hao Chiang, Kate Hsu, Chih-Kuang Chuang, Chen-Wei Kao, Yi-Fang Chang, Ming-Chih Chang, Ken-Hong Lim, Hung- Cheng, Yen-Ning Hsu, Caleb G. Chen
Summary: Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL are frontline treatments for chronic myeloid leukemia (CML) and have been shown to enhance immunity. Research has revealed that gamma delta T cells expand and increase activating molecules during TKI treatments in CML patients, suggesting a positive regulatory role in TKI responses.
BLOOD CANCER JOURNAL
(2021)
Article
Multidisciplinary Sciences
Jiahui Zhang, Cheng Ji, Hongbo Zhang, Hui Shi, Fei Mao, Hui Qian, Wenrong Xu, Dongqing Wang, Jianming Pan, Xinjian Fang, Helder A. Santos, Xu Zhang
Summary: In this study, it was found that neutrophil-derived exosomes (N-Ex) can induce tumor cell apoptosis by delivering cytotoxic proteins and activating caspase signaling pathway. By decorating N-Ex with superparamagnetic iron oxide nanoparticles (SPIONs), a higher tumor-targeting therapeutic effect can be achieved. Moreover, exosome-like nanovesicles (NNVs) were fabricated with high yield. Compared to liposome-loaded doxorubicin (DOX) and natural NNVs, DOX-loaded NNVs showed improved inhibition of tumor cell proliferation. Additionally, DOX-loaded, SPION-decorated NNVs selectively accumulated at tumor sites under an external magnetic field, effectively restraining tumor growth and significantly prolonging survival rate in mice.
Article
Oncology
David B. Rosen, Anne Mansson Kvarnhammar, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson, Enping Hong, Yu-Chi Lee, Dhruv Thakar, Luis Alejandro Zuniga, Kathy Bang, Simran Singh Sabharwal, Karan Uppal, Janne Damm Olling, Kristian Kjaergaard, Thomas Kurpiers, Meike Schnabel, Diana Reich, Philipp Glock, Joachim Zettler, Mathias Krusch, Ana Bernhard, Stefan Heinig, Valentino Konjik, Thomas Wegge, Yvonne Hehn, Steffen Killian, Laura Viet, Josefine Runz, Frank Faltinger, Mohammad Tabrizi, Kristin Laura Abel, Vibeke Miller Breinholt, Stina M. Singel, Kennett Sprogoe, Juha Punnonen
Summary: Recombinant interleukin-2 (IL-2) is an approved cancer immunotherapy, but it has severe toxicities and suboptimal pharmacokinetics. TransCon IL-2 beta/gamma is a novel prodrug designed to address these issues, showing sustained release of IL-2 and potential antitumor activity in animal models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Ching-Lien Wu, Julien Caumartin, Giada Amodio, Francois Anna, Maria Loustau, Silvia Gregori, Pierre Langlade-Demoyen, Joel LeMaoult
Summary: Invariant Natural Killer T (iNKT) cells, when activated by exogenic glycolipid antigen, can release cytokines rapidly to enhance anti-tumor activity. The presence of the tolerogenic molecule HLA-G in humans may impact the function of iNKT cells, potentially affecting the outcome of clinical trials.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Batel Sabag, Moria Levy, Jessica Kivelevitz, Nataly Dashevsky, Aviad Ben-Shmuel, Abhishek Puthenveetil, Fatima Awwad, Mira Barda-Saad
Summary: This study found that mechanotransduction plays a role in regulating signaling and activation versus inhibition balance in NK cells through the control of actin movement by the cytoskeletal component WASp. Understanding the interaction between NK cells and the tumor microenvironment is crucial for the development of immunotherapy.
Article
Multidisciplinary Sciences
Narges Aghaallaei, Advaita M. Dick, Erika Tsingos, Daigo Inoue, Eva Hasel, Thomas Thumberger, Atsushi Toyoda, Maria Leptin, Joachim Wittbrodt, Baubak Bajoghli
Summary: The study in medaka fish reveals that progenitors first enter a thymic niche favoring the development of gamma delta T cells, and the gradients of interleukin-7 and Ccl25a in the niche influence the lineage outcome. This previously unknown mechanism determines the proportion of alpha beta/gamma delta lineages within species.
Review
Oncology
Georg Gruenbacher, Martin Thurnher
FRONTIERS IN ONCOLOGY
(2018)
Article
Immunology
Georg Gruenbacher, Hubert Gander, Andrea Rahm, Gabriele Dobler, Astrid Drasche, Jakob Troppmair, Walter Nussbaumer, Martin Thurnher
FRONTIERS IN IMMUNOLOGY
(2019)
Review
Cell Biology
Oliver Nussbaumer, Martin Thurnher
Review
Urology & Nephrology
Andrea Katharina Lindner, Georg Gruenbacher, Gert Schachtner, Martin Thurnher, Renate Pichler
EUROPEAN UROLOGY FOCUS
(2020)
Article
Pharmacology & Pharmacy
Georg Gruenbacher, Hubert Gander, Gabriele Dobler, Andrea Rahm, Dominik Klaver, Martin Thurnher
Summary: The study used transcriptome and secretome profiling to analyze the signaling and function of ectopic P2Y(11) receptors, which were validated in human monocyte-derived M2 macrophages. The results showed that targeting P2Y(11) receptors can activate IL-1 receptor signaling to promote sTNFR2 release and suppress TLR4 signaling, facilitating resolution of inflammation.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Andrea Katharina Lindner, Gert Schachtner, Gennadi Tulchiner, Martin Thurnher, Gerold Untergasser, Peter Obrist, Iris Pipp, Fabian Steinkohl, Wolfgang Horninger, Zoran Culig, Renate Pichler
Summary: Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is a familial cancer syndrome with increased risk for urothelial cancer (UC) due to mismatch repair (MMR) gene mutations and microsatellite instability.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Renate Pichler, Andrea Katharina Lindner, Georg Schaefer, Gennadi Tulchiner, Nina Staudacher, Martin Mayr, Eva Comperat, Jacob J. Orme, Gert Schachtner, Martin Thurnher
Summary: Despite the low expression of PD-L1 in both tumor regions and cell types, high expression of ADAM17 was found in RC specimens obtained after BCG failure. Additionally, increased expression of GATA3, IL-10, and IL-10R suggested an immunosuppressive tumor microenvironment in BCG failure patients. This study highlights the potential role of ADAM proteases in cleaving PD-L1 from bladder tumor cells and immune cells in BCG failure cases, indicating the necessity of supplementing PD-L1 assessment with ADAM10/17.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Cell Biology
Dominik Klaver, Martin Thurnher
Summary: Macrophages are a diverse group of hematopoietic cells that play a vital role in maintaining tissue integrity. Studies have shown that the regulation of macrophage inflammatory responses by P2Y receptors is important in treating infectious diseases and cancer.
Article
Biochemistry & Molecular Biology
Dominik Klaver, Hubert Gander, Gabriele Dobler, Andrea Rahm, Martin Thurnher
Summary: This study reveals how P2Y(11) utilizes IL-1R and canonical signaling pathways to promote the anti-inflammatory and pro-angiogenic properties of human M2 macrophages.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Oncology
Andrea Katharina Lindner, Agnieszka Martowicz, Gerold Untergasser, Johannes Haybaeck, Eva Comperat, Florian Kocher, Andreas Seeber, Martin Thurnher, Renate Pichler
Summary: Localized renal cell carcinoma is usually treated surgically, and postoperative immunotherapy is used for high-risk patients. CXCR3 expression is higher in advanced tumors and is associated with increased CD8(+) T cell expression. CXCR3 could be a potential marker for predicting recurrence in renal cell carcinoma after surgery.
Review
Biochemistry & Molecular Biology
Dominik Klaver, Martin Thurnher
Summary: Although the downstream signaling pathways of the P2Y(11) receptor remain unclear, its importance in regulating inflammation and cell migration has been observed in primary immune cells. Recent studies have shown that P2Y(11) is upregulated during macrophage development and activates signaling through the IL-1 receptor, which plays a role in directing inflammatory and migratory processes. This review summarizes the first transcriptomic and secretomic analyses of P2Y(11) receptors and discusses their crosstalk with the IL-1 receptor in human M2 macrophages.
PURINERGIC SIGNALLING
(2023)